DOCSLIB.ORG

Biotechnology Corticosteroids & Hormones Synthesis Prostaglandins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

BIOTECHNOLOGY CORTICOSTEROIDS & HORMONES SYNTHESIS PROSTAGLANDINS FRANCOPIA API Name Business Unit Therapeutic class Page API Name Business Unit Therapeutic class Page Estrus synchronization Corticosteroids Alfaprostol 15% sol. Prostaglandins P. 13 Dexamethasone sodium phosphate Anti-inflammatory P. 6 (veterinary) and hormones Alimemazine tartrate Synthesis Antihistamines Systemic P. 8 Dinoprost (Prostaglandin F2 alpha) Prostaglandins Labour induction P. 13 Vasodilator, Erectile Estrus synchronization Alprostadil (Prostaglandin E1) Prostaglandins P. 13 Dinoprost tromethamine Prostaglandins P. 13 dysfunction, Sexual disorders (veterinary) Alprostadil alfadex (PGE1alfa-CD) Prostaglandins Artherosclerosis P. 13 Dinoprostone (Prostaglandin E2) Prostaglandins Labour induction P. 13 Amiodarone hydrochloride Synthesis Cardiac Therapy P. 8 Disopyramide phosphate Synthesis Cardiac Therapy P. 8 Amisulpride Synthesis Psycholeptics P. 8 DL Lysine acetyl salicylate for Oral Analgesics / Antithrombotic Synthesis P. 8 application Agents Apomorphine hydrochloride Francopia Anti-Parkinson P. 12 DL Lysine acetyl salicylate Non Sterile but Analgesics / Antithrombotic Articaine hydrochloride Synthesis Anaesthetics P. 8 Synthesis P. 8 for Injectable application Agents Beraprost sodium Prostaglandins Artherosclerosis P. 13 DL Lysine acetyl salicylate + glycine non- Analgesics / Antithrombotic Synthesis P. 9 Beta Blocking Agents / sterile grade but for Injectable application Agents Betaxolol hydrochloride Synthesis P. 8 Ophthalmologicals DL Lysine base 50 % Synthesis Intermediate P. 9 Bimatoprost Prostaglandins Anti-glaucoma P. 13 Pulmonary Arterial Epoprostenol sodium Prostaglandins P. 13 Buserelin acetate Synthesis Cytostatic Hormone Therapy P. 8 Hypertension (PAH) Corticosteroids Ethylmorphine hydrochloride Francopia Antitussives P. 12 Canrenoate Potassium Postassium-sparing diuretics P. 6 and hormones Fexofenadine hydrochloride Synthesis Antihistamines Systemic P. 9 Corticosteroids Corticosteroids Canrenone micronized Postassium-sparing diuretics P. 6 Fluorometholone Anti-inflammatory P. 6 and hormones and hormones Carbasalate calcium Synthesis Analgesics P. 8 Corticosteroids Fluorometholone micronized Anti-inflammatory P. 6 Postpartum bleeding, and hormones Carboprost tromethamine Prostaglandins P. 13 childbirth induction Corticosteroids Fluorometholone milled Anti-inflammatory P. 6 Chlorpromazine hydrochloride Synthesis Psycholeptics P. 8 and hormones Corticosteroids Ciclopirox acid powder Synthesis Antifungals Dermatological P. 8 Fluticasone propionate micronized Anti-inflammatory P. 6 and hormones Ciclopirox olamine powder Synthesis Antifungals Dermatological P. 8 Furosemide Synthesis Diuretics P. 9 Ciprofibrate Synthesis Lip.Reg. / Anti-Ath. Preps P. 8 Glibenclamide Synthesis Diabetes P. 9 Clobazam Synthesis Psycholeptics P. 8 Glimepiride Synthesis Diabetes P. 9 Estrus synchronization Cloprostenol Sodium Prostaglandins P. 13 Pituitary + Hypotham (veterinary) Gonadorelin acetate Synthesis P. 9 Hormone Clorazepate dipotassium Synthesis Psycholeptics P. 8 Human Recombinant Insulin for cells Narcotic Analgesics/ Synthesis Growth Factor for Cells Culture P. 9 Codeine base Francopia P. 12 culture application Antitussives Corticosteroids Narcotic Analgesics/ Hydrocortisone acetate micronized Anti-inflammatory P. 6 Codeine camphosulfonate Francopia P. 12 and hormones Antitussives Corticosteroids Narcotic Analgesics/ Hydrocortisone hemisuccinate Anti-inflammatory P. 6 Codeine hydrochloride Francopia P. 12 and hormones Antitussives Corticosteroids Narcotic Analgesics/ Hydrocortisone micronized Anti-inflammatory P. 6 Codeine Phosphate hemihydrate Francopia P. 12 and hormones Antitussives Corticosteroids Hydrocortisone sodium phosphate Anti-inflammatory P. 6 Concentrate of poppy straw morphine Francopia Analgesics P. 12 and hormones Corticosteroids Corticosteroids Cortisone acetate micronized Anti-inflammatory P. 6 Hydrocortisone valerate Anti-inflammatory P. 6 and hormones and hormones Cyanocobalamin Biotech Vitamin P. 14 Hydroxocobalamin acetate Biotech Vitamin P. 14 Cyanocobalamin <200µm Biotech Vitamin P. 14 Hydroxocobalamin base Biotech Vitamin P. 14 Cyanocobalamin high purity Biotech Vitamin P. 14 Hydroxocobalamin chloride Biotech Vitamin P. 14 Deflazacort micronized Biotech Antiinflamatory P. 14 Corticosteroids Hydroxy acid Anti-inflammatory P. 7 Corticosteroids and hormones Desoximetasone micronized Anti-inflammatory P. 6 and hormones Antirheumatic System / Hydroxychloroquine sulphate Synthesis P. 9 Corticosteroids Antiprotoz.& Anthelmint. Dexamethasone acetate micronized Anti-inflammatory P. 6 and hormones Analgesics / Antirheumatic Ibuprofen Lysinate Synthesis P. 9 Corticosteroids System Dexamethasone micronized Anti-inflammatory P. 6 and hormones Pulmonary Arterial Iloprost Prostaglandins P. 13 Dexamethasone sodium Corticosteroids Hypertension (PAH) Anti-inflammatory P. 6 metasulfobenzoate and hormones 2 API Name Business Unit Therapeutic class Page API Name Business Unit Therapeutic class Page Antirheumatic System / Corticosteroids Ketoprofen Synthesis P. 9 Prednisone micronized Anti-inflammatory P. 7 Analgesics and hormones Latanoprost Prostaglandins Anti-glaucoma P. 13 Promethazine hydrochloride Synthesis Antihistamines Systemic P. 10 Latonoprostene Bunod Prostaglandins Anti-glaucoma P. 13 Ramipril coated Synthesis Renin-Angioten System Agent P. 10 Leflunomide Synthesis Antirheumatic System P. 9 Ramipril powder Synthesis Renin-Angioten System Agent P. 10 Levomepromazine hydrochloride Synthesis Psycholeptics P. 9 Rifampicin (rifampin) Biotech Antibiotic P. 14 Levomepromazine maleate Synthesis Psycholeptics P. 9 Rifamycin S Biotech Intermediate P. 14 Limaprost alfadex Prostaglandins Spinal canal stenosis P. 13 Rifamycin SV Na Biotech Antibiotic P. 14 Loprazolam methanesulfonate Synthesis Psycholeptics P. 10 Riluzole Synthesis CNS Drugs P. 10 Metamizol magnesium (granules & Roxithromycin Biotech Antibiotic P. 14 Synthesis Analgesics P. 10 powder) Selegiline hydrochloride Synthesis Anti - Parkinson Preps P. 10 Metamizol sodium Synthesis Analgesics P. 10 Sevelamer carbonate Synthesis P. 10 Methylcobalamin (Mecobalamin) Biotech Vitamin P. 14 Sevelamer hydrochloride Synthesis P. 11 Corticosteroids Methylprednisolone acetate micronized Anti-inflammatory P. 7 Ophthalmologicals & Nasal and hormones Sodium cromoglicate micronized Synthesis P. 11 Preparations Corticosteroids Methylprednisolone hemisuccinate Anti-inflammatory P. 7 Ophthalmologicals & Nasal and hormones Sodium cromoglicate milled Synthesis P. 11 Preparations Corticosteroids Methylprednisolone micronized Anti-inflammatory P. 7 Ophthalmologicals & Nasal and hormones Sodium cromoglicate recrystallized milled Synthesis P. 11 Preparations Methylprednisolone sodium succinate Corticosteroids Anti-inflammatory P. 7 Sodium Hyaluronate sterile, buffered sterile and hormones Pharmaceutical grade, MW: 0.5 - 2.5 Synthesis Viscoelastic Medical Device P. 11 Methylprednisolone sodium succinate non Corticosteroids Anti-inflammatory P. 7 million Da buffered and hormones Sodium valproate Synthesis Anti - Epileptics P. 11 Postpartum bleeding, Misoprostol Prostaglandins P. 13 childbirth induction Spiramycin base Biotech Antibiotic P. 14 Narcotic Analgesics, Corticosteroids Morphine base Francopia P. 12 Spironolactone micronized Postassium-sparing diuretics P. 7 Intermediates and hormones Morphine hydrochloride Francopia Narcotic Analgesics P. 12 Sulprostone Prostaglandins P. 13 Morphine sulfate Francopia Narcotic Analgesics P. 12 Tamsulosin hydrochloride Synthesis Urologicals P. 11 Nalbuphine hydrochloride Francopia Analgesics P. 12 Teicoplanin Biotech Antibiotic P. 14 Opioid overdose/Opioid Teicoplanin Lyophilized Sterile Biotech Antibiotic P. 14 Naloxone hydrochloride Francopia P. 12 induced Constipation Antirheumatic System / Tiaprofenic acid Synthesis P. 11 Naltrexone hydrochloride Francopia Alcohol/opioid dependence P. 12 Analgesics Norepinephrin hydrochloride Ticlopidine hydrochloride Synthesis Antithrombotic Agents P. 11 Synthesis Cardiac therapy P. 10 (noradrenaline hydrochloride) Tolterodine tartrate Synthesis Urologicals P. 11 Norepinephrin hydrogentartrate Synthesis Cardiac therapy P. 10 Travoprost Prostaglandins Anti-glaucoma P. 13 (noradrenaline tartrate) Pulmonary Arterial Treprostinil sodium Prostaglandins P. 13 Noscapine Francopia Antitussives P. 12 Hypertension (PAH) Oxycodone hydrochloride Francopia Narcotic Analgesics P. 12 Corticosteroids Triamcinolone acetonide micronized Intermediate P. 7 Cerebral & Peripheric and hormones Pentoxifylline Synthesis P. 10 Vasotherapy Trimipramine maleate Synthesis Psychoanaleptics P. 11 Piretanide Synthesis Renin-Angioten System Agent P. 10 Valproic acid Synthesis Anti -Epileptics P. 11 Prednicarbate Synthesis Topical Corticosteroids P. 10 Zolpidem tartrate Synthesis Psychoanaleptics P. 11 Corticosteroids Prednisolone acetate micronized Anti-inflammatory P. 7 Zopiclone Synthesis Psychoanaleptics P. 11 and hormones Corticosteroids Prednisolone hemisuccinate Anti-inflammatory P. 7 and hormones Corticosteroids Prednisolone micronized Anti-inflammatory P. 7 and hormones Corticosteroids Prednisolone sodium metasulfobenzoate Anti-inflammatory P. 7 and hormones Corticosteroids Prednisolone sodium phosphate Anti-inflammatory P. 7 and hormones 3 Therapeutic class API Name Business Unit Page Therapeutic class API Name Business Unit Page Alcohol/opioid dependence Naltrexone hydrochloride Francopia P. 12 Corticosteroids Anti-inflammatory Hydroxy acid P. 7
Recommended publications
  • VTE) Cindy Ward, DNP, RN-BC, CMSRN, ACNS-BC

    VTE) Cindy Ward, DNP, RN-BC, CMSRN, ACNS-BC

    Chronic Complications of Venous Thromboembolism (VTE) Cindy Ward, DNP, RN-BC, CMSRN, ACNS-BC Roanoke, VA Disclosure • The speaker has no conflicts of interest to disclose. Carilion Roanoke Memorial Hospital • 3 time Magnet® designated • Flagship of Carilion Clinic, a 7 hospital system • Region’s only Level 1 Trauma Center • 703-bed academic medical center • System-wide, serves nearly 1 million patients across Virginia, West Virginia and North Carolina Objectives At the conclusion of this education activity, the learner will be able to: • recall VTE risk factors and prevention • describe post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension (CTEPH) • identify nursing implications of caring for patients with post-thrombotic syndrome and CTEPH What is VTE? Pulmonary Embolus Deep Vein (PE) Thrombosis (DVT) Signs/Symptoms of DVT • Swelling • Erythema • Pain • Warmth1 Signs/Symptoms of PE 1 • Sudden onset of dyspnea • Tachycardia • Irregular heartbeat • Chest pain, worse with deep breath • Hemoptysis • Low blood pressure, light-headedness or syncope • 350,000 – 900,000 people per year are affected by VTE1, 2 • VTE is the leading cause of preventable hospital death in the US2 • VTE can occur without symptoms (silent)3 Quick Facts • Patients with DVT who are untreated have a 37% incidence of PE that is fatal4 • Combined mortality from PE (initial and recurrence) is 73%4 Quick Facts • 1 in 20 hospitalized patients will suffer a fatal PE if they have not received adequate VTE prophylaxis5 • For 25% of patients with PE, the first
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • 16171145.Pdf

    16171145.Pdf

    CORE Metadata, citation and similar papers at core.ac.uk Provided by Radboud Repository PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/86683 Please be advised that this information was generated on 2017-12-06 and may be subject to change. OBSTETR GYNEC European Journal of Obstetrics & Gynecology ELSEV and Reproductive Biology 61 (1995) 171-173 Case report Critical limb ischemia after accidental subcutaneous infusion of sulprostone Yvonne W.C.M. de Koninga, Peter W. Plaisierb, I. Leng Tanc, Fred K. Lotgering*a aDepartment o f Obstetrics and Gynaecology, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands bDepartment o f General Surgery, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands cDepartment o f Radiology, Erasmus University, School o f Medicine and Health Sciences, EUR EE 2283, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands Received 23 September 1994; accepted 20 January 1995 Abstract A 34-year-old patient was treated with constant intravenous infusion of sulprostone because of postpartum hemorrhage from a hypotonic uterus. The arm in which sulprostone had been infused was painful 23 h after infusion. A day later, the arm was found to be blueish, edematous and extremely painful as a result of arterial spasm. The vasospasm was probably caused by accidental subcutaneous infusion of sulprostone as a result of a displaced intravenous catheter.
  • CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions

    CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions

    Review CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions Rossana Roncato 1,*,†, Jacopo Angelini 2,†, Arianna Pani 2,3,†, Erika Cecchin 1, Andrea Sartore-Bianchi 2,4, Salvatore Siena 2,4, Elena De Mattia 1, Francesco Scaglione 2,3,‡ and Giuseppe Toffoli 1,‡ 1 1 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy; [email protected] (E.C.); [email protected] (E.D.M.); [email protected] (G.T.) 2 Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; [email protected] (J.A.); [email protected] (A.P.); [email protected] (A.S-B.); [email protected] (S.S.); [email protected] (F.S.) 3 Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, 20162 Milan, Italy 4 Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy * Correspondence: [email protected]; Tel.:+390434659130 † These authors contributed equally. ‡ These authors share senior authorship. Int. J. Mol. Sci. 2020, 21, x; doi: www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, x 2 of 8 Table S1. Co-administered agents categorized according to their potential risk for Drug-Drug interaction (DDI) in combination with CDK4/6 inhibitors (CDKis). Colors suggest the risk of DDI with CDKis: green, low risk DDI; orange, moderate risk DDI; red, high risk DDI. ADME, absorption, distribution, metabolism, and excretion; GI, Gastrointestinal; TdP, Torsades de Pointes; NTI, narrow therapeutic index. * Cardiological toxicity should be considered especially for ribociclib due to the QT prolongation.
  • GTH 2021 State of the Art—Cardiac Surgery: the Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery

    GTH 2021 State of the Art—Cardiac Surgery: the Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery

    Review Article 59 GTH 2021 State of the Art—Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery Laura Ranta1 Emmanuelle Scala1 1 Department of Anesthesiology, Cardiothoracic and Vascular Address for correspondence Emmanuelle Scala, MD, Centre Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH 05/300, 1011 Switzerland Lausanne, Suisse, Switzerland (e-mail: [email protected]). Hämostaseologie 2021;41:59–62. Abstract Heparin-induced thrombocytopenia (HIT) is a severe, immune-mediated, adverse drug Keywords reaction that paradoxically induces a prothrombotic state. Particularly in the setting of ► Heparin-induced cardiac surgery, where full anticoagulation is required during cardiopulmonary bypass, thrombocytopenia the management of HIT can be highly challenging, and requires a multidisciplinary ► cardiac surgery approach. In this short review, the different perioperative strategies to run cardiopul- ► state of the art monary bypass will be summarized. Introduction genicity of the antibodies and is diagnostic for HIT. The administration of heparin to a patient with circulating Heparin-induced thrombocytopenia (HIT) is a severe, im- pathogenic HITabs puts the patient at immediate risk of mune-mediated, adverse drug reaction that paradoxically severe thrombotic complications. induces a prothrombotic state.1,2 Particularly in the setting The time course of HIT can be divided into four distinct of cardiac surgery, where full anticoagulation is required phases.6 Acute HIT is characterized by thrombocytopenia during cardiopulmonary bypass (CPB), the management of and/or thrombosis, the presence of HITabs, and confirma- HIT can be highly challenging, and requires a multidisciplin- tion of their platelet activating capacity by a functional ary approach.
  • List of Union Reference Dates A

    List of Union Reference Dates A

    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares

    Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares

    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins

    Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins

    Article Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins Márton Enesei 1,2,László Takács 2, Enik˝oTormási 3, Adrienn Tóthné Rácz 3, Zita Róka 3, Mihály Kádár 3 and Zsuzsanna Kardos 2,* 1 Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, M˝uegyetemrakpart 3, 1111 Budapest, Hungary; [email protected] 2 CHINOIN, a member of Sanofi Group, PG Development, Tó utca 1-5, 1045 Budapest, Hungary; laszlo.takacs@sanofi.com 3 CHINOIN, a member of Sanofi Group, PG Analytics, Tó utca 1-5, 1045 Budapest, Hungary; robertne.tormasi@sanofi.com (E.T.); adrienn.tothneracz@sanofi.com (A.T.R.); zita.roka@sanofi.com (Z.R.); mihaly.kadar@sanofi.com (M.K.) * Correspondence: zsuzsanna.kardos@sanofi.com Received: 15 June 2020; Accepted: 10 August 2020; Published: 18 August 2020 Abstract: Four enantiomeric forms of natural prostaglandins, ent-PGF α (( )-1), ent-PGE ((+)-2) 2 − 2 ent-PGF α (( )-3), and ent-PGE ((+)-4) have been synthetized in gram scale by Corey synthesis used 1 − 1 in the prostaglandin plants of CHINOIN, Budapest. Chiral HPLC methods have been developed to separate the enantiomeric pairs. Enantiomers of natural prostaglandins can be used as analytical standards to verify the enantiopurity of synthetic prostaglandins, or as biomarkers to study oxidation processes in vivo. Keywords: preparation; ent-PGF2α; ent-PGF1α; ent-PGE2; ent-PGE1; chiral HPLC; enantiomeric separation; mirror images; enantiopurity 1. Introduction Interest in the field of prostaglandins has been steadily growing since the basic work of Bergström Samuelsson, and Vane [1–3]. Their discoveries revealed the structure, the enzyme-controlled biochemical synthesis from arachidonic acid, and the main physiological effects of prostaglandins as well as their related substances.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).